Inactive Instrument

Press Releases Bio-Path Holdings Inc Nasdaq

Equities

US09057N2018

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

Bio-Path Holdings, Inc. Announces Closing of $1.2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules	Apr. 22	AQ
Bio-Path Holdings, Inc. Announces $1.2 Million Registered Direct Offering Priced At-theMarket Under Nasdaq Rules	Apr. 19	AQ
Bio-Path Holdings, Inc. Announces $1.2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules	Apr. 18	AQ
Bio-Path Holdings Announces Successful Completion of Higher Dose Second Cohort in Phase 1/1b Clinical Trial of BP1002 in Refractory/Relapsed Acute Myeloid Leukemia (AML) Patients	Apr. 18	AQ
Bio-Path Holdings Expands Global Patent Portfolio	Apr. 15	AQ
Bio-Path Holdings Provides 2024 Clinical and Operational Update	Apr. 02	AQ
Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q4 23	Mar. 27	NE
Bio Path : Failure to Satisfy Listing Rule - Form 8-K	Mar. 13	PU
Bio-Path Holdings Reports Full Year 2023 Financial Results	Mar. 08	AQ
Bio-Path Holdings to Announce Fourth Quarter and Full Year 2023 Financial Results on March 8, 2024	Mar. 04	AQ
Bio-Path Holdings to Announce Fourth Quarter and Full Year 2023 Financial Results on March 8, 2024	Mar. 01	AQ
Bio-Path Holdings Announces 1-for-20 Reverse Stock Split	Feb. 21	AQ
Bio-Path Holdings Announces Completion of First Dose Cohort in Phase 1 Clinical Trial Evaluating BP1002 to Treat Refractory Relapsed Lymphoma and Refractory Relapsed Chronic Lymphocytic Leukemia Patients	Jan. 11	AQ
Bio-Path Holdings Announces Completion of First Dose Cohort in Phase 1 Clinical Trial Evaluating BP1002 to Treat Refractory/Relapsed Lymphoma and Refractory/Relapsed Chronic Lymphocytic Leukemia Patients	Jan. 10	AQ
Bio-Path Holdings Successfully Completes First Dose Cohort of Phase 1/1b Clinical Trial of BP1002 in Refractory, Relapsed Acute Myeloid Leukemia	Dec. 15	AQ
Bio-Path Holdings Successfully Completes First Dose Cohort of Phase 1/1b Clinical Trial of BP1002 in Refractory/Relapsed Acute Myeloid Leukemia	Dec. 14	AQ
Bio-Path: Q3 Earnings Snapshot	Nov. 15	AQ
Bio-Path Holdings Reports Third Quarter 2023 Financial Results	Nov. 15	AQ
Bio-Path Holdings to Announce Third Quarter 2023 Financial Results on November 15, 2023	Nov. 08	AQ
Bio-Path Holdings to Host Virtual Key Opinion Leader Event to Discuss Prexigebersen and Advances in the Treatment Landscape for Acute Myeloid Leukemia	23-10-24	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Bio-Path Holdings Inc Nasdaq

Equities

US09057N2018

Press Releases

Filters